Andrea DiFabio

CIK: 0001692506

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)2 (22.2%)

Position reduction

Option Exercises (M)2 (22.2%)

Derivative conversions

Awards (A)5 (55.6%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

XENE

Xenon Pharmaceuticals Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (9 total)

XENE
Xenon Pharmaceuticals Inc.
Mar 13, 2026
Sale(S)
Direct
1.3K shares at avg. $55.23$74K
XENE
Xenon Pharmaceuticals Inc.
Mar 12, 2026
Exercise(M)
Direct
3.8K shares-
XENE
Xenon Pharmaceuticals Inc.
Mar 10, 2026
Sale(S)
Direct
2.6K shares at avg. $60.11$157K
XENE
Xenon Pharmaceuticals Inc.
Mar 9, 2026
Exercise(M)
Direct
7.5K shares-
XENE
Xenon Pharmaceuticals Inc.
Mar 9, 2026
Award(A)
Performance Share Units
Direct
7.5K shares-
XENE
Xenon Pharmaceuticals Inc.
Jan 9, 2026
Award(A)
Share Option (Right to Buy)
Direct
80K shares-
XENE
Xenon Pharmaceuticals Inc.
Jan 9, 2026
Award(A)
Restricted Share Units
Direct
15K shares-
XENE
Xenon Pharmaceuticals Inc.
Mar 12, 2025
Award(A)
Restricted Share Units
Direct
15K shares-
XENE
Xenon Pharmaceuticals Inc.
Mar 12, 2025
Award(A)
Share Option (Right to Buy)
Direct
80K shares-

		Type	Shares	Price		Ownership
Mar 13, 2026	XENE Xenon Pharmaceuticals Inc.	Sale(S)	1,342	$55.23	$74,112	Direct
Mar 12, 2026	XENE Xenon Pharmaceuticals Inc.	Exercise(M)	3,750	-	$0	Direct
Mar 10, 2026	XENE Xenon Pharmaceuticals Inc.	Sale(S)	2,607	$60.11	$156,702	Direct
Mar 9, 2026	XENE Xenon Pharmaceuticals Inc.	Exercise(M)	7,500	-	$0	Direct
Mar 9, 2026	XENE Xenon Pharmaceuticals Inc.	Award(A) Performance Share Units	7,500	-	-	Direct
Jan 9, 2026	XENE Xenon Pharmaceuticals Inc.	Award(A) Share Option (Right to Buy)	80,000	-	-	Direct
Jan 9, 2026	XENE Xenon Pharmaceuticals Inc.	Award(A) Restricted Share Units	15,000	-	-	Direct
Mar 12, 2025	XENE Xenon Pharmaceuticals Inc.	Award(A) Restricted Share Units	15,000	-	-	Direct
Mar 12, 2025	XENE Xenon Pharmaceuticals Inc.	Award(A) Share Option (Right to Buy)	80,000	-	-	Direct

1-9 of 9 transactions

About DiFabio Andrea

DiFabio Andrea (SEC CIK 0001692506) files insider reports with the SEC as Chief Legal Officer of Xenon Pharmaceuticals Inc. (XENE).

Signal8 holds 4 ownership filings by DiFabio Andrea, all Form 4s, filed between Mar 13, 2025 and Mar 13, 2026. Those filings report 9 transactions, from Mar 12, 2025 to Mar 13, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on DiFabio Andrea's filings is in BURNABY, A1.

Recent filings by DiFabio Andrea

Mar 13, 2026: Open-market sale of XENE shares (Form 4, code S).
Mar 12, 2026: Option exercise of XENE shares (Form 4, code M).
Mar 10, 2026: Open-market sale of XENE shares (Form 4, code S).
Mar 9, 2026: Option exercise of XENE shares (Form 4, code M).
Mar 9, 2026: Grant or award of XENE derivative securities (Form 4, code A).

Other insiders filing for Xenon Pharmaceuticals Inc. (XENE)

Kelly Thomas Patrick, Chief Financial Officer
MORTIMER IAN, PRESIDENT & CEO
Svoronos Dawn, Director
GANNON STEVEN, Director
PATOU GARY, Director
Cannon Gillian, Director

How to read Form 4 transaction codes